Seoul, July 8: South Korea’s biopharmaceutical exports are on track to post a record performance in the first half of the year, driven by strong global demand for high-value medicines and contract manufacturing services.
The country’s biopharmaceutical sector has continued its upward momentum, supported by increased exports of biologic drugs, biosimilars and contract development and manufacturing (CDMO) services. Industry experts attribute the growth to South Korean companies expanding their global footprint and securing new overseas partnerships.
The robust export performance highlights South Korea’s growing position as a key player in the global biopharmaceutical industry, with continued investments in advanced manufacturing capabilities and research helping the sector remain competitive.
Analysts expect exports to maintain their positive trajectory in the coming months, backed by sustained international demand and a healthy pipeline of innovative products.
